제어로봇시스템학회논문지 (Journal of Institute of Control, Robotics and Systems)

  • 제10권6호
  • /
  • Pages.475-486
  • /
  • 2004
  • /
  • 1976-5622(pISSN)
  • /
  • 2233-4335(eISSN)
제어로봇시스템학회 (Institute of Control, Robotics and Systems)
권호 표지
DOI QR코드

DOI QR Code

HIV 동역학과 최적 제어를 이용한 약물 치료에 관한 고찰

A Study on Dong Scheduling Using HIV Dynamics and Optimal Control

  • 허영희 ((주)삼성전자 DM사업부) ;
  • 고지현 (한양대학교 전자전기컴퓨) ;
  • 김진영 (한양대학교 전자전기컴퓨) ;
  • 남상원 (한양대학교 전자전기컴퓨) ;
  • 심형보 (서울대학교 전기공학) ;
  • 정정주 (한양대학교 전자전기컴퓨터)
  • 발행 : 2004.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The interaction of HIV and human immune system was studied in the perspective of dynamics. We summarized the recent researches on drug scheduling using optimal control theory for HIV treatment. The drug treatment to make immune system to work properly is investigated based on mathematical models including memory CTLp. In the simulation results, it was verified that stopping medication after a certain period of treatment can lead a patient to be cured naturally by one s immune system. Also, we summarized and categorized the advantages and disadvantages of each HIV drug scheduling method. In conclusion, model-based predictive control is more efficient for making decision of drug dose than other methods, when there exist uncertainties on model parameters or state variables.

키워드

참고문헌

  1. D. Pieribone, 'The HIV life cycle,'
  2. C. A. Janeway, 'Immunobiology,' Garland Churchill Living-stone, 2001
  3. D. Wodarz and M. A. Nowak, 'Mathematical models of HIV pathogenesis and treatment,' Bioessays, vol. 24, pp. 1178-1187, 2002 https://doi.org/10.1002/bies.10196
  4. D. Wodarz and M. A. Nowak, 'Specific therapy regimes could lead to long-term immunological control of HIV,' PNAS, vol. 96, pp. 14464-14469, December 1999 https://doi.org/10.1073/pnas.96.25.14464
  5. D. Wodarz, 'Helper-dependent vs. helper-independent CTL responses in HIT infection: implications for drug therapy and resistance,' J. Theor. Biol., vol. 213, pp. 447-459, August 2001 https://doi.org/10.1006/jtbi.2001.2426
  6. J. A. M. Felippe de Souza, M. A. L. Caetano and T. Yoneyama, 'Analysis of a sub-optimal scheme of drug dosage in the AIDS treatment,' In proceedings of American Control Conference, pp. 1188-1193, Denber, Colorado, June 2003 https://doi.org/10.1109/ACC.2003.1239749
  7. Y. T. Yang, P. W. Lee, K. W. Choi, K. H. Kim, and M. J. Kim, 'AIDS : 본체, 현황 및 대책,' 1988
  8. M. E. Brandt and G. Chen, 'Feedback control of a biodynamical model of HIV-1,' IEEE Trans. on biomedical Engineering, vol. 48, pp. 754-759, July 2001 https://doi.org/10.1109/10.930900
  9. R. F. Stengel, R. Ghigliazza, N. Kulkarni and O. laplace, 'Optimal control of a viral disease,' In proceedings of American Control Conference, vol. 5, pp.3795-3800, June 2001 https://doi.org/10.1109/ACC.2001.946229
  10. J. A. M. Felippe de Souza, M. A. L. Caetano and T. Yoneyama, 'Optimal control theory applied to the anti-viral treatment of AIDS,' In proceedings of Conference on Decision and Control, pp. 4839-4844, Sydney, December 2000 https://doi.org/10.1109/CDC.2001.914696
  11. J. J. Kutch and P. Gurfil, 'Optimal control of HIV infection with acontinuously-mutating viral population,' Proceedings of the American Control Conference, pp. 4033-4038, Anchorage, May 2002 https://doi.org/10.1109/ACC.2002.1024560
  12. R. Zurakowski and A. R. Teel, 'Enhancing immune response to HIV infection using MPC-based treatment scheduling,' In proceedings of American Control Conference, Denber, June 2003 https://doi.org/10.1109/ACC.2003.1239748
  13. H. Shim, S. J. Han, C. C. Chung, S. W. Nam and J. H. Seo, 'Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control,' To appear in International Journal of Control, Automation and Systems, vol. 1, no. 3, September 2003
  14. D. Wodarz and M. A. Nowak, 'CD8 memory, immunodominance, and antigenic escape,' Eur. J. Immunol., vol. 30, pp. 2704-2712, September 2000 https://doi.org/10.1002/1521-4141(200009)30:9<2704::AID-IMMU2704>3.0.CO;2-0
  15. D. Wodarz and D. C. Krakauer, 'Defining CTL-induced pathology : implications for HIV,' Virology, vol. 274, pp. 94-104, August 2000 https://doi.org/10.1006/viro.2000.0399
  16. National Institute of Allergy and Infectious Diseases, 'How HIV causes AIDS,' (06 June, 2003)
  17. F. Hoffmann-La Roche Ltd, 'What is HIV?,' (18 June, 2002)
  18. J. A. Aberg et. al. 'HIV insite knowledge base,'
  19. J. A. Sullivan, 'Human Immunodeficiency Virus(HIV): overview,'
  20. R. B. Moss, F. C. Jensen and D. J. Carlo, 'Insights into HIV-specific immune function: implications for therapy and prevention in the new millennium,' Clin. Immunol., vol. 95, pp. 79-84, May 2000 https://doi.org/10.1006/clim.2000.4856
  21. D. Wodarz and V. A. A. Jansen, 'The role of T cell help for anti-viral CTL resonses,' J. theor. Biol., vol. 211, pp. 419-432, May 2001 https://doi.org/10.1006/jtbi.2001.2358
  22. R. F. Stengel, R. Ghigliazza and N. Kulkarni, 'Optimal enhancement of immune response,' Bioinformatics, vol. 18, pp. 1227-1235, March 2002 https://doi.org/10.1093/bioinformatics/18.9.1227
  23. R. F. Stengel, R. Ghigliazza, N. Kulkarni and O. Laplace, 'Optimal control of innate immune response,' Optical Control Applications and Methods, vol. 23, pp. 91-104, January 2002 https://doi.org/10.1002/oca.704